Braxia buys KetaMD to get into remote-delivered ketamine treatments

Braxia Scientific is a Toronto-based company that focuses on depression, suicidality and related mental health conditions. Today, the company announced it is buying KetaMD to extend its telehealth prowess and in particular to expand its tech-facilitated ketamine-based treatments from its current local market of Florida into the wider U.S. The deal is worth around $6 million, the company told TechCrunch.
KetaMD’s telemedicine platform provides access to affordable at-home ketamine treatments for people suffering from anxiety, depression and related mental health conditions. The company’s

リンク元